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Abstract 
 
Background:  Nephrolithiasis is a severe health problem causing morbidity. Chemolisis, extracorporeal shock wave lithotripsy 
(SWL), percutaneous nephrolithotomy (PNL), retrograde ureterorenoscopy (URS), and open and laparoscopic surgery are used for 
treatment with various success rates. Medical treatments with fewer complications were investigated thoroughly.  
Materials and Methods: In this study, we evaluated the effects of Persea americana (avocado) leaves and Viburnum opulus (guelder 
rose) fruits on nephrolithiasis in an animal model and used 42 rats. The groups received both low and high doses of Persea americana 
leaves and Viburnum opulus fruit ethanol extracts orally for 28 days. These two plants have been used for years in Turkey for their 
nephrolithiatic effect.  
Results: Avocado and guelder rose increased the urine volume and urine citrate levels, decreased urine cystine and oxalate levels, and 
lowered the crystal deposits in kidney tissue. Avocado and guelder rose also prevented oxidant damage and crystal formation in kidney 
tissue samples.  
Conclusion: The two plants that have been used for years for nephrolithiasis treatment in Turkey can safely be used for kidney stones. 
 
Key words: kidney stones; nephrolithiasis; Persea americana; Viburnum opulus; treatment 
 
 
Introduction  
 
The prevalence of nephrolithiasis was reported as 8.8% with a significant increase in the worldwide prevalence and incidence 
especially in the last 25 years (Curhan, 2007; Pearle et al., 2014a). Nephrolithiasis is a severe health problem with an incidence of 
3/1000/yr for men and 2.5/1000/yr for women (Curhan, 2007). The risk of nephrolithiasis is 5-9% in Europe, and the risk increases by 
going west, e.g., Canada and United States have reached 12-15% (Aggarwal et al., 2013). Chemolisis, extracorporeal shock wave 
lithotripsy (SWL), percutaneous nephrolithotomy (PNL), retrograde ureterorenoscopy (URS), and open and laparoscopic surgery are 
used for nephrolithiasis treatment with various success rates depending on size, location, and composition of the stones (Türk et al., 
2014). 
On the other hand, diet therapies and pharmacologic therapies are used with or without these previous treatments (Pearle et al., 
2014b). The diet therapy includes drinking enough water to facilitate at least daily 2L micturition, reducing the intake of protein and salt, 
and avoiding foods with high oxalate content (Nouvenne, 2008). Thiazide diuretics, potassium citrate, allopurinol, and tiopronin drugs 
are used as pharmacological therapies to decrease the amount of calcium, uric acid, and oxalate, and to increase the amount of citrate, 
urine pH, phosphate, and pyrophosphate in urine to reduce stone formation (Xu et al., 2013; Marangella et al., 2008).  
 Herbal treatments were found to be effective on nephrolithiasis in many studies (Patel et al., 2012a; Nizami et al., 2012). The 
researchers evaluated the efficacy of herbal medication that has been used in their countries for years for the treatment of nephrolithiasis.  
We evaluated two of the herbs that are used in our country for nephrolithiasis treatment: Persea americana leaves and 
Viburnum opulus fruits. No scientific studies evaluating their antinephrolithiatic effect were found in the literature. Thus, we evaluated 
the antinephrolithiatic effect of an ethanol extract of leaves of Persea americana and fruits of Viburnum opulus on a rat nephrolithiasis 
model. 
 
 
Material and Methods 
Collection and Identiﬁcation of Plant Materials 
  
Persea americana leaves (avocado: AVCD) were collected from Rize, Turkey, and Viburnum opulus fruits (guelder rose: 
GLBR) were collected from Kayseri, Turkey between May 2014 and June 2014. The leaves and the fruits were dried under conditions 
without exposure to direct sunlight.  
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Preparation of Ethanol Extracts 
  
 Persea americana leaves (AVCD) and Viburnum opulus fruits (GLBR) were milled and extracted by the same procedure. 
AVCD and GLBR were extracted by 500 g with 5000 mL of solvent for 8 hours. Ethanol – water (90:10) mixture was used as a solvent, 
which was circulated continuously. Extraction temperature was adjusted to 40°C. The extracts were ﬁltered. The solvent parts of the 
solutions were evaporated under reduced pressure in a rotary evaporator separately. Then the residues were dried in an oven at 60°C for 
12 hours. Pure extracts were obtained. Solutions were prepared with pure extracts in PEG 200 (50% PEG200 and 50% water solution). 
Finally, concentrations of solutions were adjusted to 10 mg/mL. 
 
 Animals and Experimental Model 
 
The study was conducted using 42 male rats (Spraque-Dawley) weighing between 250 and 300 grams aged 10 to 12 weeks old. 
The rats were housed in stainless steel cages at 21-22C and 45-50% humidity under artificial lighting with a 12-hour light/dark cycle. 
All of the groups were fed with standard rodent chow containing 24% protein ad libitum. The rats were observed daily throughout the 
study. All animal procedures were approved by the Institutional Committee on the Care and Use of Animals of our institution. The study 
was also reviewed and approved by the Ethical Committee on Animal Research. 
 An ethylene glycol model was used to induce urolithiasis for 28 days in all groups (Marangella et al., 2008). Forty-two animals 
were randomly divided into six groups: guelder rose low dose (GLBR_LD) (n=8), guelder rose high dose (GLBR_HD) (n=8), avocado 
low dose (AVCD_LD) (n=8), avocado high dose (AVCD_HD) (n=8), vehicle group (n=5), and a sham group (n=5). All low-dose groups 
received 0.5 ml, and high-dose groups received 1 ml of the extract orally for five days a week during a one-month period. The sham 
group received 1 ml of 0.9% saline, and the vehicle group received 1 ml of PEG200 (50% PEG200 and 50% water solution) orally for 
five days a week for four weeks. All groups received calculi inducing treatment for 28 days, which contained 0.75% v/v ethylene glycol 
in drinking water ad libitum. 
 
Urine, Blood Collection, and Biochemical Analysis 
 
 Animals were kept in metabolic cages, and 24-hour urine samples were collected on the 28th day of the experiment. The 
volume, pH, and crystalluria were determined. Urine was collected into plastic tubes and stored at -20C. Urine uric acid, urea, 
creatinine, calcium, magnesium, sodium, potassium, and chloride levels were determined with an Olympus AU2700 autoanalyzer using 
its own kits (Beckman Coulter GmbH, Krefeld, Germany). Urine citrate and oxalate levels were analyzed using HPLC kits (Eureka Lab 
Division Chiaravalle, Ancona, Italy). Urine cystine levels were analyzed with an Amino Acid Analyzer ARACUS (MembraPure GmbH, 
Berlin, Germany). The urine samples were evaluated under a light microscope for the amount of crystal formation and nucleation. 
 After the experimental period, blood was collected from the aorta under gas anesthesia, and the animals were sacrificed. Serum 
was separated by centrifugation at 4000g for 10 minutes and analyzed with an Olympus AU2700 analyzer (Olympus Co.Ltd. Tokyo, 
Japan). The urea, creatinine, calcium, phosphorus, and magnesium levels were tested using commercially available diagnostic kits. 
 
Kidney Histopathology and Homogenate Analysis 
 
 The left kidney was removed for histopathological analyses and fixed in 10% buffered formaldehyde and blocked using 
paraffin. After the routine pathological procedures, 5-μm thickness slides were prepared. The slides were stained with hematoxylin and 
eosin (H&E), and then were examined under light microscopy using a specialized pathologist blinded to treatments. The parameters 
including tubular, glomerular, interstitial, and vascular changes that were used for scoring are detailed in Table 2. The scoring for casts 
was done by the method described by Patel, Patel, Vyas, Shah, and Gandhi (2012) (Patel et al., 2012b). In addition, the hematoxylin and 
eosin sections were prepared, and the representative figures are shown in Figure 1. The crystal depositions were counted and scored by a 
light microscope using a polarized ﬁlter (Figure 2). 
 The right kidney was removed for antioxidant enzyme analysis. Frozen tissues were homogenized in phosphate buffer (pH 7.4) 
on an ice cube, by a homogenizer (Heidolph Silent Crusher M, Heidolph Instruments, Schwabach, Germany). The supernatant was stored 
at −80°C. µQuant (Biotek Instruments, Winooski, VT, USA) and used for spectrophotometric measurements. The kidney tissue 
homogenate was used for malondialdehyde (MDA) (Okhawa et al., 1979), glutathione peroxidase (GSH) (Paglia et al., 1967), and 
superoxide dismutase assays (Sun et al., 1988). The MDA levels are expressed as mmol/gprotein. GSH-Px activity is expressed as 
U/gprotein. The calculated SOD activity is expressed as U/gprotein. 
 
Statistical Analysis 
 
 Statistical analyses were conducted using SPSS statistical software (SPSS for Windows, Version 10.0; SPSS Inc., Chicago, IL). 
The Kruskal-Wallis test was used for variance analyses between groups. Subgroup analyses were performed using the Bonferroni 
adjusted Mann-Whitney U test. P<0.05 was considered to be significant in homogeneous groups.  
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Results 
  
The urine outputs of the AVCD and GLBR groups were statistically increased as compared with the sham and vehicle groups 
(p<0.05). However, there was no difference among low and high doses (p>0.05) (Figure 4). The urea and creatinine levels were normal 
both in serum and urine. 
The vehicle (PEG) group increased urine cystine and oxalate levels, but decreased citrate levels. Although urine citrate levels 
were increased in AVCD and GLBR, it was not statistically significant (p>0.05) (Figure 4). AVCD and GLBR decreased the urine 
cystine and oxalate levels, the statistical significance of which is given in Table 1.  The vehicle group increased urine calcium, uric acid, 
and phosphate levels. GLBR and AVCD decreased the urine calcium levels in both low and high doses, but they were not statistically 
significant (p>0.05). GLBR_LD increased the urine calcium levels as compared with the vehicle group. GLBR_LD increased the urine 
magnesium levels (p<0.05) (Table 1). The MDA levels in GLBR_HD were significantly decreased as compared with the sham and 
vehicle groups (p<0.05). Superoxide dismutase levels in AVCD_HD were significantly high as compared with the vehicle group 
(p<0.05). The GSH-Px levels in AVCD_LD, AVCD_HD, and GLBR_HD were significantly high as compared with the vehicle group 
(p<0.05). The GSH-Px level in AVCD_HD was significantly high as compared with the sham group (p<0.05) (Figure 5). The kidney 
weight in the vehicle group was statistically higher than all groups (p<0.05). AVCD and GLBR decreased the kidney weight in the 
vehicle as compared with the vehicle group (p<0.05). The kidney weight in low-dose groups was statistically decreased as compared to 
high-dose groups (p<0.05). The kidney weights of all the low- and high-dose study groups were higher than the sham group, except 
GLBR_LD (p<0.05). (Figure 5). The hematoxylin and eosin section examinations revealed focal mild vacuolar changes in the tubular 
epithelial cells in the sham group and prominent vacuolar changes and flattening in the tubular epithelial cells and hyaline casts in some 
samples in the vehicle group. In AVCD-HD and GLBR-HD, tubular epithelial cell changes were similar to the vehicle group, but all 
changes were moderate. In AVCD-LD and GLBR-LD, tubular epithelial cell changes were similar to AVCD-HD, but all changes were 
milder than those of the HD groups (Figure 1, H&E, x200 for all panels).There were no crystal depositions in tubules of the sham group. 
However, there were prominent crystals in the tubules of the vehicle group. In AVCD_HD and GLBR_HD, crystal depositions in the 
tubules were lower than the vehicle group, but higher than the LD groups (Figure 2, H&E with polarized, x200 for all panels). The 
pathologic scores of the AVCD and GLBR groups both in LD and HD were significantly lower than the vehicle group (p<0.05). The 
pathologic scores of the AVCD_LD and GLBR_LD groups were significantly lower than the AVCD_HD and GLBR_HD groups 
(p<0.05) (Table 2). 
 
 
 
Discussion 
 
Nephrolithiasis is a major health problem causing severe morbidity, and surgical treatments have potentially serious 
complications. Thus, new treatments with fewer potential complications were evaluated in-depth. We evaluated the antinephrolithiatic 
effect of Persea americana and Viburnum opulus. We clearly showed that avocado and guelder rose increased the urine volume and urine 
citrate levels, decreased urine cystine and oxalate levels, and lowered the crystal deposits in kidney tissue. 
Dietary, pharmacological, and surgical interventions are commonly used treatments for nephrolithiasis. However, there are side 
effects of these treatments that may cause morbidity and increased risk of hypertension, stroke, and gout in the withdrawals; 
multicomponent diet, gastrointestinal upset, erectile dysfunction, fatigue, muscle symptoms, anemia, headache, tremor and deep venous 
thrombosis in the pharmacological interventions; and urosepsis, fever, bleeding, urinary leakage, renal injury, and ureteral perforation in 
the surgical interventions (Türk et al., 2014; Qaseem, 2014). Thus, medical treatments with fewer side effects have been evaluated for 
years. 
 The majority of kidney stones are calcium oxalate with a lesser amount of magnesium phosphate and, in very small amounts, 
urate and cystine (Aggarwal et al., 2013). The very first phase of kidney stone formation is the super-saturation of the urine with elements 
such as calcium, oxalate, cystine, and urate. With the addition of oxidative stress and uroepithelial cell injury, the process gains speed, 
and the crystal formation and aggregation results in stone formation. Citrate inversely inhibits CaOx crystals to bind the uroepithelial cell 
membrane (Lieske et al., 1995). 
We evaluated urine calcium, magnesium, phosphate, oxalate, cystine, and citrate. AVCD and GLBR lowered urinary calcium 
and phosphate excretion in our study. In addition, AVCD and GLBR increased the urine volume and urine citrate levels, decreased urine 
cystine and oxalate levels, and lowered the crystal deposits in kidney tissue. 
We suggest that AVCD and GLBR were efficient in preventing kidney stone formation by preventing super-saturation of the 
initiator elements such as calcium, magnesium, phosphate, oxalate, cystine, and citrate. High doses of AVCD and GLBR lowered MDA 
levels and increased SOD levels. Both AVCD and GLBR increased GPx levels. These findings suggest that AVCD and GLBR also 
prevented stone formation via inhibiting uroepithelial damage by oxidant injury. One of the major steps in kidney stone formation is 
crystal formation and aggregation. Although the initiating factor is not clearly known, this process cannot be easily stopped before stone 
formation. Once the crystal forms, its nuclei in supersaturated urine, proteins, casts, and epithelial cells promote the formation. The 
process finishes with a well-shaped crystal (Aggarwal et al., 2013). Therefore, the shape of the crystal can give us information about the 
stone formation process. We found that the groups receiving AVCD and GLBR had abnormal and small crystals. However, the crystals 
in the vehicle group were well defined (Figure 3). Thus, we suggest that AVCD and GLBR also inhibited stone formation via preventing 
crystal formation. Herbal treatments have been used for years as a folk remedy for the treatment of nephrolithiasis. Herniaria hirsuta, 
Phyllanthus niruri, Dolichos biflorus, Quercus salicina Blume/Quercus stenophylla Makino, Punica granatum, Vaccinium macrocarpon, 
and Andrographis paniculata were reported as herbs that decreased renal stone formation in earlier in vitro studies, in vivo studies, and 
clinical trials (Butterweck et al., 2009). In most of these studies, the effect of the herbal treatment was reported via increased urinary 
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volume with diuretic effect; a decrease of excretion of urinary calcium and oxalate; and an inhibition of calcium oxalate crystallization or 
anti-oxidative action (Butterweck et al., 2009). In Turkey, Persea americana leaves and Viburnum opulus fruits are two of the herbs 
commonly used for the treatment of nephrolithiasis. However, there have been no previous scientific studies proving this effect. We 
clearly showed that Persea americana leaves and Viburnum opulus fruits in both low and high doses inhibited renal stone formation by 
increasing urine citrate and decreasing urine cystine and oxalate excretion, thereby inhibiting calculi and stone formation. Urine output 
was increased nearly two-fold in the study groups as compared with the sham group. Thus, one of the major antinephrolithiatic effects of 
these herbs was due to polyuria. The weak part of the study was primarily dependent on the animal model. The model was not able to 
show aggressive stone formation via preventing urinary flow, thereby causing stone formation in pooled urine and in the parenchyma of 
the kidney. Because the model allows free urinary flow, the urea and creatinine were also normal. In histopathology, we could not see 
much crystal formation in renal tissue as described earlier in detail. However, the tubular and interstitial changes were much clearer. The 
pathological scores of the AVCD and GLBR groups were lower than the vehicle, and LD groups were lower than HD groups. This 
finding demonstrates that AVCD and GLBR do well in preventing stone formation, but dose increment has no additional effect. The total 
pathologic score showed that these herbs clearly decreased stone formation via preventing tubular and interstitial damage. In conclusion, 
avocado and guelder rose have antinephrolithiatic effect by increasing the urine volume, increasing urine citrate, and decreasing cystine 
and oxalate levels. The additional possible mechanism may be via preventing oxidant damage and crystal formation. These beneficial 
effects still need to be confirmed in large human studies using various doses.  
 
 
 
 
 
Figure 1: [A] Sham group; focal mild vacuolar changes can be seen in the tubular epithelial cells. [B] Vehicle and sham groups; 
prominent vacuolar changes and flattening were seen in the tubular epithelial cells. In some, hyaline casts were detected. [C] 
AVCD_HD; tubular epithelial cell changes were similar to the vehicle and sham groups, but all changes were moderate. [D] AVCD_LD; 
tubular epithelial cell changes were similar to AVCD_HD, but all changes were milder than those of AVCD_HD. [E] C: GLBR_HD 
group; tubular epithelial cell changes were similar to AVCD_HD, but all changes were milder than the vehicle and sham groups. [F] 
GLBR_LD; tubular epithelial cell changes were similar to GLBR_HD, but all changes were milder than those of GLBR_HD like 
AVCD_LD (H&E, x200 for all panels). 
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Figure 2: The appearance of crystal depositions: [A] Sham group; no crystal seen in the tubules. [B] Vehicle and sham groups; 
prominent crystals in the tubules. [C] AVCD_HD; crystal depositions in the tubules were lower than vehicle and sham group, but higher 
than AVCD_LD. [D] AVCD_LD; crystal depositions in the tubules not much higher than those of AVCD_HD. [E] C: GLBR_HD; 
crystal depositions in the tubules were similar to AVCD_HD, but lower than vehicle and sham groups. [F] GLBR_LD; crystal 
depositions in the tubules not much higher than those of GLBR_HD like AVCD_LD (H&E with polarized, x200 for all panels). 
  
 
 
 
 
Figure 3: The crystal formation was observed with a light microscope at the end of the experiment (40X). [A] The sham group showed 
no crystal formation. [B] The vehicle sham group showed extensive amount of crystal formation. The crystals are larger in dimension, 
and the crystal nucleation was clearly visible. The amount of crystal present and nucleation in [C] AVCD_LD, [D] AVCD_HD, [E] 
GLBR_LD, and [F] GLBR_HD groups was lower in LD groups than HD and the sham group. AVCD and GLBR decreased the crystal 
nucleation and amount. 
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Figure 4: The cystine, oxalate, citrate levels and urine volume of the study groups. The symbols represent * : different from sham group, 
# : different from vehicle group. 
 
 
 
Figure 5: The kidney weight and antioxidant enzyme levels were represented. The symbols represent * : different from sham group, # : 
different from vehicle group. 
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Table 1: The urine and serum parameters of the study and control groups 
Urinary Parameters AVCD_LD AVCD_HD GLBR_LD GLBR_HD Sham Vehicle Control p 
Urine output (ml/24 
h) 
22.50 
(15-29) 
18.50 
(12-21) 
20.00 
(15-29) 
16.50 
(10-21) 
14.50 
(12-22) 
15.00 
(12-18) 
0.011
& 
0.016
** 
0.016
£
 
0.019*** 
Calcium  
(mg/24 h) 
1.66 
(0.49-3.28) 
1.57 
(0.49-3.34) 
2.28 
(1.68-2.99) 
1.07 
(0.40-2.86) 
1.27 
(0.72-2.57) 
2.01 
(0.95-2.72) 
0.02
$
 
Uric acid  
(mg/24 h) 
0.04 
(0.00-0.30) 
0.09 
(0.00-0.14) 
0.20 
(0.09-0.52) 
0.10 
(0.00-0.20) 
0.12 
(0.00-0.22) 
0.90 
(0.28-1.44) 
0.03# 
0.02** 
0.12$$ 
0.002*** 
0.004**** 
Phosphate  
(mg/24 h) 
0.15 
(0.05-1.70) 
0.21 
(0.02-0.39) 
0.24 
(0.03-1.18) 
0.89 
(0.10-6.42) 
0.14 
(0.04-4.90) 
3.08 
(0.16-7.56) 
>0.05 
Magnesium (mg/24 
h) 
2.63 
(0.65-5.07) 
2.68 
(0.40-4.21) 
4.38 
(0.95-7.35) 
0.28 
(0.02-3.65) 
1.92 
(0.02-5.11) 
1.59 
(0.41-3.24) 
0.022
$$
 
Urea  
(g/24h) 
957.47 
(763.79-1199.79) 
880.32 
(665.34-1017.40) 
1129.71 
(875.57-1412.58) 
999.02 
(794.59-1162.00) 
1027.82 
(824.63-1244.95) 
994.22 
(879.44-11382.52) 
>0.05 
Creatinine 
8614.58 
(6559.28-10272.08) 
9635.60 
(7770.36-10678.72) 
7399.08 
(4154.80-10227.88) 
9162.66 
(8017.88-10855.52) 
9984.78 
(7045.48-11730.68) 
9149.40  
(6497.40-10935.08) 
0.032
$ 
0.07
$ 0.02
£
 
Citrate  
(mg/24 h) 
8.68 
(3.15-14.48) 
4.51 
(0.71-13.24) 
9.80 
(2.17-61.10) 
6.63 
(2.29-16.77) 
15.42 
(1.28-29.40) 
5.15 
(3.63-7.70) 
>0.05 
Oxalate  
(mg/24 h) 
132.80 
(31.00-288.06) 
166.74 
(3.10-259.80) 
150.15 
(52.42-322.50) 
162.50 
(37.99-331.53) 
45.50  
(0.73-72.12) 
250.85 
(179.29-351.12) 
0.02& 
0.043** 
0.005$ 
Cystine  
(umol/24 h) 
3.51 
(1.38-8.20) 
2.15 
(1.05-11.31) 
2.49 
(1.19-8.52) 
2.18 
(0.81-4.39) 
1.08 
(0.54-2.66) 
4.02 
(3.47-4.17) 
0.005* 
0.02**
 
0.035
$$ 
0.029*** 
        
Serum parameters  
Urea  
(mg/dl) 
41.5 
(36.00-52.00) 
47.00 
(38.00-61.00) 
55.00 
(44.00-68.00) 
42.00 
(38.00-62.00) 
68.00 
(62.00-77.00) 
47.00 
(39.00-51.00) 
0.002*0.
020
&
0.02
$
 
0.03
$$ 
0.002
£
 
0.006**** 
Creatinine  
(mg/dl) 
0.42 
(0.37-0.48) 
0.51 
(0.35-0.63) 
0.54 
(0.48-0.59) 
0.42 
(0.37-0.47) 
0.47 
(0.38-0.55) 
0.41 
(0.35-0.52) 
0.002* 
0.020
& 
 
0.021
$ 
0.012
$$
 
0.045
£
 
Calcium  
(mg/dl) 
8.89 
(8.25-9.58) 
9.36 
(7.58-9.76) 
9.59 
(9.04-9.81) 
9.17 
(6.96-10.28) 
9.24 
(7.93-9.79) 
9.59 
(8.49-10.50) 
>0.05 
Phosphorus (mg/dL) 
4.88 
(2.62-7.07) 
6.92 
(3.73-9.25) 
6.62 
(5.80-9.08) 
6.47 
(4.43-7.78) 
5.54 
(4.37-6.01) 
6.24 
(4.41-8.00) 
0.028
# 
0.007
$
 
Magnesium (mg/dl) 
2.24 
(1.85-2.46) 
2.58 
(1.87-2.86) 
2.48 
(2.11-2.69) 
2.39 
(1.73-2.67) 
2.28 
(2.20-2.44) 
2.24 
(1.72-2.60) 
>0.05 
Abbreviations: LD: Low dose, HD: High dose, ALT: alanine aminotransferase     AST: aspartate aminotransferase,  Na: Sodium,  K: Potassium *1-5, 
#
1-6, &2-5, **2-6, $3-5, 
$$
3-6, 
£
4-5, ***4-6, ****5-6 
 
Erdem et al., Afr J Tradit Complement Altern Med. (2016) 13(2):110-119 
http://dx.doi.org/10.4314/ajtcam.v13i2.14 
117 
 
 
 
 
 
 
 
Table 2:. Kidney weight and antioxidant enzyme levels of the kidney tissue 
Kidney Parameters AVCD_LD AVCD_HD GLBR_LD GLBR_HD Sham Vehicle control p 
Kidney weight (gm) 
2.53  
(1.96-3.41) 
3.45  
(3.16-4.10) 
2.79  
(1.60-3.38) 
3.67  
(2.38-4.40) 
1.65  
(1.34-3.58) 
4.88  
(3.49-5.52) 
<0.05ψ 
<0.05Φ 
MDA (mmol/gpro) 
0.599  
(0.94-0.906) 
0.92  
(0.01-2.82) 
0.848  
(0.311-3.182) 
0.130  
(0.0-0.438) 
0.445  
(0.387-0.682) 
0.762  
(0.368-1.544) 
0.007
£ 
0.007*** 
SOD 
(U/gpro) 
1059.2  
(869.2-1853.8) 
1100.2  
(901.6-1302.3) 
1176.5  
(897.5-2671.1) 
1107.2  
(882.5-1469.4) 
1099.1  
(845.1 -1290.8) 
815.75  
(562.2-1036.0) 
0.038** 
GPx 
(U/gpro) 
227.8  
(179.7-320.9) 
244.4  
(194.2-300.8) 
218.9  
(116.9-448.2) 
227.6  
(211.0-240.4) 
205.2  
(157.1 -233.0) 
205.4  
(89.9-211.2) 
0.04
# 
0.028
& 
0.013** 
0.021*** 
MDA: malondialdehyde, SOD: Superoxide dismutase, GSH: reduced glutathione, Φ for all sham group comparisons ψ for all vehicle group comparisons, *1-5, 
#
1-6, &2-5, **2-6, $3-5, 
$$
3-6, 
£
4-5, ***4-6, ****5-6 
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Table 3: Histologic scoring of study groups. 
Group 
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N
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E
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h
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l 
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n
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Casts 
R
e
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o
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C
ry
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o
s
it
io
n
  
E
d
e
m
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C
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s
ti
o
n
 
H
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o
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h
a
g
e
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a
m
m
a
ti
o
n
 
V
a
s
c
u
lit
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F
ib
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n
o
id
 n
e
c
ro
s
is
 
F
ib
ro
in
ti
m
a
l 
th
ic
k
e
n
in
g
 
E
ry
th
ro
c
y
te
 
H
y
a
lin
e
 
AVCD-HD 1 0 0 0 0 0 1 1.5 0 1.3 0 0.9 1 3 7.6 1.1 1.4 0 0.8 3.3 0 0 0 0 11.9*# 
AVCD-LD 1 0 0 0 0 0 1 1.5 0 1.1 0 1.1 0.4 2 6.1 1 1 0 0.3 2.3 0 0 0 0 9.4*# 
GLBR-HD 1 0 0 0 0 0 1 1 0 1 0 1.1 0.4 3 6.5 1 1 0 0.8 2.8 0 0 0 0 10.3*# 
GLBR-LD 1 0 0 0 0 0 1 1 0 1 0 1 0.7 2 5.7 1 1 0 0.7 2.7 0 0 0 0 9.4*# 
Sham 1 0 0 0 0 0 1 1 0 0 0 1 0 0 2 0.7 0.7 0 0.7 2 0 0 0 0 5.0* 
Vehicle 
Control 
1 0 0 0 0 0 1 1 0 0 0 1 0 0 12.0 1 1 0 0.7 5.0 0 0 0 0 16.6# 
 
0:Normal/No pathological changes 
1: Focal* and segmental 
2: Focal and global 
3: Diffuse and segmental 
4: Diffuse** and global 
*The involvement restricted in less 
than 50 % of glomeruli 
**The involvement restricted in more 
than 50 % of glomeruli 
0: Normal/No pathological 
changes 
1:Focal and mild 
2: Focal and severe 
3: Diffuse and mild 
4: Diffuse and severe 
Scoring for crystal 
deposition:  
0:<1; 1:<10; 2:<30; 3:<50; 
4:<75 
Scoring for casts:  
0: No changes; 1:<25%; 
2:26-50%; 3:51-75%; 4:>75 
0: Normal/No pathological changes 
1:Focal and mild 
2: Focal and severe 
3: Diffuse and mild 
4: Diffuse and severe 
0: Normal/No pathological 
changes 
1:Minimal 
2: Mild 
3: Moderate 
4: Severe 
*p<0.05 for sham group comparisons 
#p<0.05 for vehicle group comparisons 
& p<0.05 for LD and HD comparisons 
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